Monte Rosa Therapeutics Inc. Common Stock (GLUE)
Stock · NASDAQ · Health Care
$9.76as of 10/16/2026
Price chart
Active signals
GLUE Signal Track Record
How signals performed across all stocks →What GLUE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | +4.7% | 61% | October 1, 2026 |
| Bollinger Band Breakdown | 26 | +3.6% | 58% | September 15, 2026 |
| Bollinger Band Breakout | 25 | -8.3% | 40% | June 23, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -4.6% | 25% | July 18, 2025 |
| Any 20-session window (baseline) | -2.0% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GLUE
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and sy…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 173
- Website
- www.monterosatx.com/
Fundamentals
- 1-day range
- $9.88$10.24
- Market cap
- $1.33B
- P/E (trailing)
- —
- P/E (forward)
- -5.20
- EPS (trailing)
- $-1.74
- Dividend yield
- —
- Beta
- 1.35
- Avg. volume
- 1.36M
How Monte Rosa Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 17, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Monte Rosa Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- GLUEMonte Rosa Therapeutics Inc. Common Stock$9.74▼ 3.75%Market cap $1.33BP/E —$8.94$25.77
- VORVor Biopharma Inc. Common Stock$18.03▼ 6.77%Market cap $1.28BP/E 1.82$6.5$33.42
- NVAXNovavax Inc. Common Stock$11.26▼ 12.17%Market cap $1.27BP/E —$6.2$13.39
- IMTXImmatics N.V. Ordinary Shares$6.73▼ 5.74%Market cap $1.26BP/E —$6.73$12.41
- INBXInhibrx Biosciences Inc. Common Stock$89.83▼ 0.74%Market cap $1.26BP/E —$28.16$155.29
- ALVOAlvotech Ordinary Shares$5▼ 5.84%Market cap $1.19BP/E —$2.94$9.05
- MGTXMeiraGTx Holdings plc Ordinary Shares$9.28▼ 6.17%Market cap $1.18BP/E 11.93$6.62$15.35
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GLUE Monte Rosa Therapeutics Inc. Common Stock | $1.33B | — | $9.74 | ▼ 3.75% | $8.94$25.77 |
| VOR Vor Biopharma Inc. Common Stock | $1.28B | 1.82 | $18.03 | ▼ 6.77% | $6.5$33.42 |
| NVAX Novavax Inc. Common Stock | $1.27B | — | $11.26 | ▼ 12.17% | $6.2$13.39 |
| IMTX Immatics N.V. Ordinary Shares | $1.26B | — | $6.73 | ▼ 5.74% | $6.73$12.41 |
| INBX Inhibrx Biosciences Inc. Common Stock | $1.26B | — | $89.83 | ▼ 0.74% | $28.16$155.29 |
| ALVO Alvotech Ordinary Shares | $1.19B | — | $5 | ▼ 5.84% | $2.94$9.05 |
| MGTX MeiraGTx Holdings plc Ordinary Shares | $1.18B | 11.93 | $9.28 | ▼ 6.17% | $6.62$15.35 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 StudyYahoo · 10/6/2026
- Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk - SlideshowSeekingAlpha · 10/5/2026
- HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price TargetBenzinga · 10/5/2026
- Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk TranscriptSeekingAlpha · 10/1/2026
- Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular DiseaseBenzinga · 10/1/2026
- Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD RiskYahoo · 10/1/2026
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga · 10/1/2026
Insider Activity
Insider Actions →- Matthew Bowen · October 5, 2026 · Sale13 @ $10.56
- Markus Warmuth · July 16, 2026 · Sale9.5K @ $23.18
- Jennifer Champoux · July 15, 2026 · Option Exercise4.4K @ $3.98
- Jennifer Champoux · July 15, 2026 · Sale4.4K @ $23.38
- Sharon Townson · July 6, 2026 · Option Exercise6.0K @ $6.14
- Sharon Townson · July 6, 2026 · Sale400 @ $24.13
- Sharon Townson · July 6, 2026 · Sale5.6K @ $23.25
- Ali Behbahani · July 1, 2026 · J15.0K
- Ali Behbahani · July 1, 2026 · J1.00M
- Filip Janku · June 30, 2026 · Option Exercise5.4K @ $13.41
- Filip Janku · June 30, 2026 · Sale5.4K @ $24.5
- Filip Janku · June 24, 2026 · Option Exercise30.0K @ $7.56
- Filip Janku · June 24, 2026 · Sale30.0K @ $21.42
- Filip Janku · June 23, 2026 · Option Exercise6.0K @ $7.56
- Filip Janku · June 23, 2026 · Sale11.8K @ $20.22
Institutional Ownership
March 31, 2026
- Total shares held
- 86.17M
- Total value held
- $1.30B
- Institutional holders
- 184
- Unknown7.69M
- Unknown6.72M
- Unknown5.64M
- Unknown4.62M
- Unknown4.46M
- Unknown4.35M
- Unknown4.23M
- Unknown3.60M
- Unknown3.35M
- Unknown3.21M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Monte Rosa draws analyst attention on pipeline review and routine disclosures
Recent coverage for Monte Rosa Therapeutics has focused on the company's drug pipeline and balance sheet position, alongside standard disclosures. The company reported inducement grants to employees under a Nasdaq listing rule, which is a routine corporate event. Separately, Monte Rosa announced participation in upcoming investor conferences, giving management a venue to update the market on its clinical programs. Together, these items keep the company visible to investors without altering its underlying outlook.
Monte Rosa draws analyst attention on pipeline review and routine disclosures. Recent coverage for Monte Rosa Therapeutics has focused on the company's drug pipeline and balance sheet position, alongside standard disclosures. The company reported inducement grants to employees under a Nasdaq listing rule, which is a routine corporate event. Separately, Monte Rosa announced participation in upcoming investor conferences, giving management a venue to update the market on its clinical programs. Together, these items keep the company visible to investors without altering its underlying outlook.